PL3487505T3 - Podawanie i dawkowanie diaminofenotiazyn - Google Patents

Podawanie i dawkowanie diaminofenotiazyn

Info

Publication number
PL3487505T3
PL3487505T3 PL17743330.7T PL17743330T PL3487505T3 PL 3487505 T3 PL3487505 T3 PL 3487505T3 PL 17743330 T PL17743330 T PL 17743330T PL 3487505 T3 PL3487505 T3 PL 3487505T3
Authority
PL
Poland
Prior art keywords
diaminophenothiazines
dosage
administration
Prior art date
Application number
PL17743330.7T
Other languages
English (en)
Inventor
Claude Michel Wischik
Björn Olaf SCHELTER
Damon Jude Wischik
John Mervyn David Storey
Original Assignee
Wista Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59399428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3487505(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1612863.9A external-priority patent/GB201612863D0/en
Priority claimed from GBGB1710382.1A external-priority patent/GB201710382D0/en
Application filed by Wista Laboratories Ltd. filed Critical Wista Laboratories Ltd.
Publication of PL3487505T3 publication Critical patent/PL3487505T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/20Agglomerating; Granulating; Tabletting
    • A23P10/28Tabletting; Making food bars by compression of a dry powdered mixture
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/30Encapsulation of particles, e.g. foodstuff additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00Decoration means, markings, information elements, contents indicators
    • B65D2203/02Labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Botany (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Composite Materials (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
PL17743330.7T 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn PL3487505T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612863.9A GB201612863D0 (en) 2016-07-25 2016-07-25 Administration and dosage of diaminophenothiazines
GBGB1710382.1A GB201710382D0 (en) 2017-06-29 2017-06-29 Administration and dosage of Diaminophenothiazines
PCT/EP2017/068749 WO2018019823A1 (en) 2016-07-25 2017-07-25 Administration and dosage of diaminophenothiazines

Publications (1)

Publication Number Publication Date
PL3487505T3 true PL3487505T3 (pl) 2023-10-09

Family

ID=59399428

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17743330.7T PL3487505T3 (pl) 2016-07-25 2017-07-25 Podawanie i dawkowanie diaminofenotiazyn

Country Status (18)

Country Link
US (4) US11065256B2 (pl)
EP (3) EP4223297A3 (pl)
JP (1) JP7073330B2 (pl)
KR (4) KR102592614B1 (pl)
CN (2) CN116531386A (pl)
AU (3) AU2017301966B2 (pl)
CA (1) CA3031578A1 (pl)
DK (1) DK3487505T3 (pl)
ES (1) ES2946165T3 (pl)
FI (1) FI3487505T3 (pl)
HR (1) HRP20230628T1 (pl)
MX (2) MX2019000946A (pl)
MY (1) MY201804A (pl)
PL (1) PL3487505T3 (pl)
PT (1) PT3487505T (pl)
SG (1) SG11201900228YA (pl)
SI (1) SI3487505T1 (pl)
WO (1) WO2018019823A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2057136T3 (da) 2006-07-11 2013-08-26 Wista Lab Ltd Fremgangsmåde til syntese og/eller oprensning af diaminophenothiazinium forbindelser
SG11201900228YA (en) * 2016-07-25 2019-02-27 Wista Lab Ltd Administration and dosage of diaminophenothiazines
EP3826639A1 (en) 2018-07-26 2021-06-02 WisTa Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations
WO2020048593A1 (en) 2018-09-05 2020-03-12 Wista Laboratories Ltd. Network methods for neurodegenerative diseases
CA3134588A1 (en) * 2019-04-10 2020-10-15 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
KR20230012515A (ko) * 2020-05-05 2023-01-26 위스타 레보레이토리스 리미티드 유익한 치료방법
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024061971A1 (en) 2022-09-21 2024-03-28 Wista Laboratories Ltd. Novel formulations and vehicles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
PT1799662E (pt) 2004-09-23 2013-07-09 Wista Lab Ltd Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
PL2004155T3 (pl) * 2006-03-29 2018-08-31 Wista Laboratories Ltd. Inhibitory agregacji białek
CN101460222B (zh) 2006-03-29 2013-12-04 维斯塔实验室有限公司 锍化合物及其用途
EP2013191B3 (en) * 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
DK2057136T3 (da) 2006-07-11 2013-08-26 Wista Lab Ltd Fremgangsmåde til syntese og/eller oprensning af diaminophenothiazinium forbindelser
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
JP5725605B2 (ja) * 2007-06-19 2015-05-27 ウイスタ・ラボラトリーズ・リミテッドWista Laboratories Ltd. 軽度認知障害を処置するためのフェノチアジン化合物
DK2954932T3 (en) 2007-10-03 2018-12-17 Wista Lab Ltd THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES
WO2010078659A1 (en) 2009-01-12 2010-07-15 Foster Health Inc. Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
CA2773306C (en) 2009-09-24 2018-04-24 Wista Laboratories Ltd. Process for the preparation of substantially pure methylthioninium chloride pentahydrate form a
SG10201408584UA (en) 2009-09-24 2015-02-27 Wista Lab Ltd Crystalline Methylthionium Chloride Hydrates
AU2011334679B2 (en) 2010-11-30 2016-12-15 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
HUE031633T2 (en) 2011-02-11 2017-07-28 Wista Lab Ltd Phenothiazine diaminium salts and their use
SG11201900228YA (en) * 2016-07-25 2019-02-27 Wista Lab Ltd Administration and dosage of diaminophenothiazines
EP3826639A1 (en) 2018-07-26 2021-06-02 WisTa Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations

Also Published As

Publication number Publication date
KR102475825B1 (ko) 2022-12-08
US20220008431A1 (en) 2022-01-13
MX2021009899A (es) 2021-09-14
AU2022291420B2 (en) 2024-05-09
PT3487505T (pt) 2023-06-07
KR20240074909A (ko) 2024-05-28
CA3031578A1 (en) 2018-02-01
SG11201900228YA (en) 2019-02-27
EP4335517A2 (en) 2024-03-13
AU2022291420A1 (en) 2023-02-02
JP7073330B2 (ja) 2022-05-23
EP4223297A2 (en) 2023-08-09
AU2023203084A1 (en) 2023-06-08
WO2018019823A8 (en) 2018-04-05
AU2017301966B2 (en) 2022-09-22
US20200016165A1 (en) 2020-01-16
KR20230003261A (ko) 2023-01-05
KR20190031552A (ko) 2019-03-26
KR20230058533A (ko) 2023-05-03
CN116531386A (zh) 2023-08-04
FI3487505T3 (fi) 2023-06-05
KR102592614B1 (ko) 2023-10-24
EP3487505B1 (en) 2023-05-03
US20230346794A1 (en) 2023-11-02
MY201804A (en) 2024-03-19
WO2018019823A1 (en) 2018-02-01
DK3487505T3 (da) 2023-05-30
SI3487505T1 (sl) 2023-10-30
US11065256B2 (en) 2021-07-20
EP3487505A1 (en) 2019-05-29
MX2019000946A (es) 2019-05-13
EP4223297A3 (en) 2023-11-15
JP2019527216A (ja) 2019-09-26
ES2946165T3 (es) 2023-07-13
AU2017301966A1 (en) 2019-03-07
HRP20230628T1 (hr) 2023-09-29
CN109789148A (zh) 2019-05-21
US11759469B2 (en) 2023-09-19
US20230165877A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
ZA202102219B (en) Dosage and administration of non-fucosylated anti-cd40 antibodies
PL3487505T3 (pl) Podawanie i dawkowanie diaminofenotiazyn
HK1249103B (zh) 多環氨甲醯基吡啶酮化合物及其藥物用途
IL251834B1 (en) Pharmaceutical compositions containing peptide variants and methods of using them
IL287749A (en) Compositions for administering implantable drugs and methods of their use
GB201817116D0 (en) Pharmaceutical preparation of palbociclic and preparation method thereof
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
RS65120B1 (sr) Farmaceutske formulacije i postupci za njihovu upotrebu
EP3498280A4 (en) ADMINISTRATION AND DOSAGE OF A THERAPEUTIC AGENT FOR ENDOMETRIOSIS
HK1246689A1 (zh) 溴莫尼定和噻嗎洛爾的固定劑量組合
ZA201805977B (en) Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof
HK1245644B (zh) 投予特拉萬星的劑量和方法
HK1223630A1 (zh) 抗- 療法的實施與用量
GB201406172D0 (en) Therapy and pharmaceutical composition
PT3503885T (pt) Composição farmacêutica e métodos de utilização
GB201519644D0 (en) Therapy and pharmaceutical composition
ZA201902085B (en) Medicinal use of serrulatane diterpenes
PL3328385T3 (pl) Postać dawkowania leku alkaloidu barwinka
GB201710382D0 (en) Administration and dosage of Diaminophenothiazines
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
IL252080A0 (en) Oral administration of drugs that are unstable or poorly absorbed